Cancer
Aromatase inhibitors
Drugs that block the conversion of androgens to oestrogen in fat and other tissues, the main source of oestrogen after menopause; standard treatment for hormone receptor-positive breast cancer in postmenopausal women, at a cost to bone.
Mechanism of action
- After menopause, most oestrogen is made outside the ovaries by aromatase, which converts androstenedione and testosterone to oestrone and oestradiol.
- Anastrozole and letrozole inhibit aromatase reversibly; exemestane inactivates it.
- Oestrogen levels fall very low, so receptor-positive tumour cells lose their growth signal.
- In premenopausal women the ovaries would compensate, so ovarian suppression is needed.
Molecular targets
- Aromatase (CYP19): Inhibitor
Drugs in Aromatase inhibitors
Non-steroidal (reversible)
- Anastrozole (Non-steroidal.)
- Letrozole (Non-steroidal.)
Steroidal (irreversible)
- Exemestane (Steroidal, irreversible.)
Therapeutic uses
- Hormone receptor-positive breast cancer after menopause: adjuvant and metastatic
- Reducing breast cancer risk in high-risk postmenopausal women
Diseases it treats
Adverse effects
- Bone loss and fractures
- Joint pain and stiffness
- Hot flushes
- Raised cholesterol
Contraindications by condition
- Osteoporosis (Use with care): Removing the last oestrogen accelerates bone loss; bone density is checked and a bisphosphonate or denosumab added.
- Premenopausal women without ovarian suppression (Contraindicated): The ovaries simply make more oestrogen.
- Pregnancy (Contraindicated): They harm the fetus.
Connected topics
Written from
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 35, Anticancer Drugs, Aromatase inhibitors
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 40, The Gonadal Hormones & Inhibitors, Aromatase inhibitors
Educational reference. Not medical advice, diagnosis or treatment.